ClinicalTrials.gg
CompletedNCT06389513Updated Aug 13, 2026

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

A Phase 4 interventional study of MCV4 in Epidemic Meningitis, sponsored by CanSino Biologics Inc.. Completed at 1 site in China. Open to participants aged 3 Months to 3 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by CanSino Biologics Inc. · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,011
Allocation
Not applicable
Ages
3 Months to 3 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Meningitis, Meningococcal with a site in China — 5 open to participants now, 8 under way, 5 of them phase 3. Meningitis, Meningococcal · China.

Enrollment
Largest of 19
3,011 · median 840
Started
2024
with 3 others
Phase 4
2 of 19
none open now
Registered
13th of 19
by date
Lead sponsor
6 of 19
CanSino Biologics Inc.

Among the 19 studies in Meningitis, Meningococcal with a site in China, this one has the largest enrollment, is one of 4 that started in 2024, is one of 2 in phase 4, and was the 13th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

5 of the 19 studies in Meningitis, Meningococcal with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 3 Months to 3 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Meningitis, Meningococcal with a site in China, or all of them as a file.
02

Study summary

This study is an open, multicenter Phase IV clinical study to evaluate the safety of vaccination with Menhycia®. The study plan is to enroll approximately 3,000 infants at 3 months of age who have not been vaccinated with any epidemic encephalitis vaccine, and to administer a total of 3 doses of Menhycia®, with a minimum of 1 month between doses, and a booster dose of 1 dose of immunization is allowed at 12 months of age.

03

Conditions studied

  • Epidemic Meningitis

Keywords

  • Vaccine
  • ACYW135
  • CRM197
  • Safety
  • 3 months of age
04

Who can participate

Ages eligible
3 Months to 3 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants 3 months of age who had not received any epidemic encephalitis vaccine at the time of screening
  • The legal guardian or delegate has given , has voluntarily signed an informed consent form, and is able to comply with the requirements of the clinical study protocol

Exclusion criteria

Exclusion Criteria:

First dose exclusion criteria

  • Fever before vaccination, axillary temperature >37.0°C
  • Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
  • History of epilepsy, convulsions or seizures or history or family history of psychiatric disorders
  • Acute infections or active chronic diseases, severe infectious or allergic skin diseases
  • Known allergy to a component of the vaccine, especially to diphtheria toxoid, or to previous administration of the product
  • Other circumstances that, in the judgment of the investigator, make participation in this clinical study inappropriate

Subsequent dose exclusion criteria

  • Severe allergic reactions after a previous dose of vaccine
  • Those with serious adverse reactions causally related to the previous dose of vaccination
  • Other circumstances that, in the judgment of the investigator, make participation in this clinical study inappropriate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3,011 participants (actual)

Study arms

  • Experimental
    ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4)

    Intramuscular injection, 0.5ml

    Biological: MCV4

Interventions

  • BiologicalMCV4

    4 doses of vaccine on Day 0, Day30, Day 60 and Month 12

06

What researchers measure

Primary outcomes

  1. Incidence of localized adverse reactions in subjects

    Time frame: Within 7 days after each dose of vaccination

  2. Incidence of systemic adverse reactions in subjects

    Time frame: Within 7 days after each dose of vaccination

Secondary outcomes

  1. Incidence of adverse reactions in subjects

    Time frame: Within 30 days after each dose of vaccination

  2. Incidence of adverse events in subjects

    Time frame: Within 30 days after each dose of vaccination

  3. Incidence of severe adverse events

    Time frame: Through study completion, an average of 10 months

07

Study locations

1 site
  • Nanjing Luhe District Center for Disease Control and Prevention Center for Disease Control and Prevention
    Nanjing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Apr 2026, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2024
First posted
Apr 29, 2024
StartActual
Jun 12, 2024
Primary completionActual
Apr 10, 2026
CompletionActual
May 1, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06389513
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Jun 12, 2024
Primary completion
Apr 10, 2026
Completion
May 1, 2026
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion